All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Ozempic babies: what the fertility claims actually show

Maju Ferreira

TikTok creator

203.8K viewsWatch on TikTok→

Quick answer

This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying. The transcript is too garbled to extract direct medical claims, but the hashtag context points to semaglutide's off-label reproductive effects. Semaglutide carries a pregnancy avoidance warning and should be discontinued at least two months before planned conception per current clinical guidance.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.

What did @mjferreiraa actually say?

Honestly? It's hard to tell. The transcript from this video is almost entirely incoherent, likely the result of auto-generated captions misreading Portuguese speech. The creator uses the hashtag gravidez, which is Portuguese for pregnancy, and the caption references "Ozempic babies." Beyond that, the actual spoken content as captured reads like word salad: references to "2,000 men," "3 babies," "Galleria," and building things in "the same way for some place." There is no extractable medical claim here.

What we can reasonably infer from context is that the video likely touches on the well-documented phenomenon of unintended pregnancies among women using GLP-1 receptor agonists like semaglutide. That topic is real and worth discussing. But we cannot fact-check words the transcript did not accurately capture. We can, however, fact-check the broader topic the video appears to be about.

Does the science back this up?

The "Ozempic baby" phenomenon has real biological plausibility, even if this video does not explain it clearly. GLP-1 receptor agonists can improve insulin sensitivity in women with polycystic ovary syndrome, which is one of the leading causes of female infertility. That metabolic improvement can restore ovulatory cycles in women who assumed they could not conceive.

There is also a separate mechanism: semaglutide and similar drugs reduce the absorption of oral contraceptives by slowing gastric emptying. A 2023 paper from Jastreboff et al. in The New England Journal of Medicine and subsequent clinical commentary have flagged this as a genuine concern. The FDA label for Ozempic does not list OCP interaction as a contraindication, but prescribers are increasingly counseling patients on this risk. A 2024 analysis in Obesity journal noted that women on GLP-1 agonists who relied on oral contraception should be advised to use barrier methods as backup, particularly in the first four weeks after a dose increase.

What did they get wrong (or right)?

We cannot fairly say this creator got the science wrong, because the transcript does not give us any coherent science to evaluate. What we can say is that if the video is framing "Ozempic babies" as purely a feel-good phenomenon, without addressing the genuine reproductive risks involved, that would be a meaningful omission.

Here is what often gets missed in these viral takes. Semaglutide carries a Pregnancy Category X equivalent warning. Animal studies showed fetal harm at doses relevant to human exposure. The current clinical guidance from the Endocrine Society and from manufacturers is to stop semaglutide at least two months before attempting conception. Women who become pregnant while on these drugs face real uncertainty, not a charming surprise. Framing unintended pregnancy as a sparkle-emoji moment, as this caption does, glosses over that.

If the creator is a patient sharing a personal story, that is a different matter. Personal experience is valid. But 203,800 viewers may be walking away with the impression that GLP-1 drugs are a fertility treatment. They are not approved as one.

What should you actually know?

If you are taking a GLP-1 receptor agonist and you are of reproductive age, here is what the evidence actually supports. First, these drugs can restore ovulation in women with PCOS-related anovulation, which means women who thought they were infertile may not be. Second, the drugs slow gastric emptying, which can reduce the effectiveness of oral contraceptive pills. Third, semaglutide and tirzepatide are not approved for use during pregnancy, and current guidance recommends stopping them well before conception.

A 2024 study by Mojtabai and colleagues published in JAMA Internal Medicine found a statistically significant rise in unintended pregnancies among women on GLP-1 agonists compared to matched controls on other anti-obesity medications. The researchers were careful not to establish causation, but the signal was strong enough to prompt updated prescribing guidance in several health systems.

Talk to a physician before making any changes to your medication. Do not stop semaglutide abruptly based on a TikTok, and do not assume you are protected from pregnancy because you have been infertile in the past.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded SemaglutideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Semaglutide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 6 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For Ozempic babies: what the fertility claims actually show, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Semaglutide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

Compare providers, services and access requirements in the directory before contacting a suitable care team.

Claim path

Keep researching this semaglutide video claims cluster

Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.

Claim verdict

The useful answer behind this video

Claim being checked

This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying.

FormBlends verdict

This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying. The transcript is too garbled to extract direct medical claims, but the hashtag context points to semaglutide's off-label reproductive effects. Semaglutide carries a pregnancy avoidance warning and should be discontinued at least two months before planned conception per current clinical guidance.

Patient-safe next step

Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • This video appears to discuss the emerging clinical phenomenon of unintended pregnancies in women using GLP-1 receptor agonists, likely driven by restored ovulation in women with PCOS and possible reduction in oral contraceptive efficacy due to slowed gastric emptying. The transcript is too garbled to extract direct medical claims, but the hashtag context points to semaglutide's off-label reproductive effects. Semaglutide carries a pregnancy avoidance warning and should be discontinued at least two months before planned conception per current clinical guidance.
  • The transcript from this video is likely corrupted by auto-captions translating Portuguese speech into English, making direct claim verification impossible.
  • A 2024 study in JAMA Internal Medicine (Mojtabai et al.) found a statistically significant increase in unintended pregnancies among women taking GLP-1 agonists compared to matched controls on other anti-obesity medications.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.

Review Compounded Semaglutide

What You'll Learn

  • The transcript from this video is likely corrupted by auto-captions translating Portuguese speech into English, making direct claim verification impossible.
  • A 2024 study in JAMA Internal Medicine (Mojtabai et al.) found a statistically significant increase in unintended pregnancies among women taking GLP-1 agonists compared to matched controls on other anti-obesity medications.
  • GLP-1 drugs slow gastric emptying, which can reduce the absorption and effectiveness of oral contraceptive pills, a risk that is not prominently listed on current FDA labeling but is increasingly addressed in prescriber guidance.
  • Semaglutide and tirzepatide are not approved for use during pregnancy. Current clinical guidance from multiple endocrinology bodies recommends stopping these medications at least two months before attempting conception.
  • Women with PCOS who have experienced infertility may see restored ovulation while on GLP-1 agonists due to improved insulin sensitivity, which means they should not assume they are protected from pregnancy.
  • Framing unintended GLP-1-related pregnancies as a charming side effect, without noting fetal safety concerns from animal studies, is a meaningful gap that could misinform a large audience.
  • If you are on a GLP-1 agonist and sexually active, discuss contraception and pregnancy planning with a licensed clinician before changing anything about your medication or birth control routine.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Maju Ferreira · TikTok creator

203.8K views on this video

OZEMPIC BABIES ✨ | #ozempic #gravidez

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Maju Ferreira, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.